Gulf International Bank UK Ltd raised its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 1.3% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 45,360 shares of the biotechnology company’s stock after purchasing an additional 600 shares during the period. Gulf International Bank UK Ltd’s holdings in BioMarin Pharmaceutical were worth $4,029,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Dimensional Fund Advisors LP grew its position in shares of BioMarin Pharmaceutical by 30.2% during the third quarter. Dimensional Fund Advisors LP now owns 288,770 shares of the biotechnology company’s stock worth $28,004,000 after acquiring an additional 66,986 shares during the last quarter. Renaissance Technologies LLC grew its position in shares of BioMarin Pharmaceutical by 627.0% during the third quarter. Renaissance Technologies LLC now owns 206,971 shares of the biotechnology company’s stock worth $20,070,000 after acquiring an additional 178,500 shares during the last quarter. Pacer Advisors Inc. grew its position in shares of BioMarin Pharmaceutical by 62.4% during the third quarter. Pacer Advisors Inc. now owns 9,180 shares of the biotechnology company’s stock worth $890,000 after acquiring an additional 3,528 shares during the last quarter. Captrust Financial Advisors purchased a new position in shares of BioMarin Pharmaceutical during the third quarter worth approximately $316,000. Finally, Teachers Advisors LLC grew its position in shares of BioMarin Pharmaceutical by 19.3% during the third quarter. Teachers Advisors LLC now owns 779,903 shares of the biotechnology company’s stock worth $75,627,000 after acquiring an additional 126,415 shares during the last quarter.

In other BioMarin Pharmaceutical news, CEO Jean Jacques Bienaime sold 4,000 shares of the firm’s stock in a transaction on Friday, April 12th. The stock was sold at an average price of $89.12, for a total value of $356,480.00. Following the completion of the sale, the chief executive officer now owns 325,211 shares of the company’s stock, valued at $28,982,804.32. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Henry J. Fuchs sold 2,196 shares of the firm’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $95.00, for a total value of $208,620.00. Following the completion of the sale, the insider now directly owns 142,504 shares of the company’s stock, valued at approximately $13,537,880. The disclosure for this sale can be found here. In the last three months, insiders sold 97,011 shares of company stock valued at $8,878,668. 1.90% of the stock is owned by corporate insiders.

Shares of NASDAQ BMRN opened at $83.16 on Friday. The company has a current ratio of 3.93, a quick ratio of 2.92 and a debt-to-equity ratio of 0.28. BioMarin Pharmaceutical Inc. has a 1-year low of $79.13 and a 1-year high of $106.74.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings results on Thursday, February 21st. The biotechnology company reported ($0.02) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.09) by $0.07. BioMarin Pharmaceutical had a negative return on equity of 2.79% and a negative net margin of 5.18%. The firm had revenue of $353.00 million during the quarter, compared to the consensus estimate of $377.35 million. During the same period last year, the company earned $0.03 earnings per share. The company’s revenue for the quarter was down 1.4% on a year-over-year basis. On average, equities research analysts expect that BioMarin Pharmaceutical Inc. will post 0.02 EPS for the current fiscal year.

BMRN has been the topic of a number of research reports. ValuEngine lowered shares of BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Wednesday, February 20th. Robert W. Baird set a $120.00 target price on shares of BioMarin Pharmaceutical and gave the stock a “buy” rating in a research report on Tuesday, April 2nd. Oppenheimer lowered their target price on shares of BioMarin Pharmaceutical from $92.00 to $81.00 in a research report on Friday, February 22nd. Cowen restated a “buy” rating on shares of BioMarin Pharmaceutical in a research report on Monday, January 7th. Finally, BidaskClub upgraded shares of BioMarin Pharmaceutical from a “strong sell” rating to a “sell” rating in a research report on Thursday, February 28th. Two analysts have rated the stock with a sell rating, five have given a hold rating and fifteen have issued a buy rating to the stock. BioMarin Pharmaceutical presently has a consensus rating of “Buy” and a consensus target price of $114.82.

WARNING: This piece was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of US & international copyright legislation. The original version of this piece can be read at https://www.watchlistnews.com/biomarin-pharmaceutical-inc-bmrn-holdings-boosted-by-gulf-international-bank-uk-ltd/2979066.html.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

See Also: Why is the conference call important?

Institutional Ownership by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.